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Abstract
Background: Protein Kinase C (PKC) is a serine/threonine kinase that involved in controlling of many cellular processes 
such as cell proliferation and differentiation. We have observed previously that TPA (12-O-tetradecanoylphorbol 13-
acetate) induces cell cycle arrest in G0/G1 phase in human hepatoma HepG2 cells. However, is there any miRNA 
involved in PKCα mediated cell growth arrest is still unknown.
Methods: We first surveyed 270 miRNA expression profiles in 20 pairs of human hepatoma tissues. We identified 11 up-
regulated and 23 down-regulated miRNAs (FDR < = 0.01; fold-change > = 2) in human hepatoma tissue after Student's 
T-test and Mann-Whitney rank test. We then examined miRNAs expression profile in TPA treated HepG2 cells. Two 
miRNAs, miR-101, and miR-29c, were shown to be significantly down regulated in human hepatoma tissues and 
induced over 4-fold in HepG2 cells under TPA treatment.
Results: In this study, we examined TPA regulated miRNA expression profile in human hepatoma HepG2 cells. We 
identified two miRNAs, 101 and 29c, were induced by TPA and down regulated in human hepatoma tissues suggest 
that they might play as tumor suppressor gene and in tumor formation of HCC. Since induction kinetics of miR-101 by 
TPA was much faster than miR-29c suggests that the induction of miR-101 may be the primary response of TPA 
treatment. We then further investigated how miR-101 was regulated by TPA. MiR-101 targets two subunits of PRC2 
complex, enhancer of zeste homolog 2 (EZH2) and EED, and was shown to play as a tumor suppressor gene in human 
prostate, breast and liver cancers. The target sequence of miR-101 located in the 3' UTR of both EZH2 and EED's mRNA 
was identified by bioinformatic analysis and was validated by reporter luciferase activity assay. Then we showed that 
TPA not only up regulated miR-101 expression, but also reduced protein level of EZH2, EED and H3K27me3 in HepG2 
cells. Using lenti-virus-mediated shRNA to knockdown endogenous PKCα expression, we observed that TPA induced 
growth arrest, elevation of miR-101 and reduction of EZH2, EED and H3K27me3 proteins were all PKCα dependent. 
Specific inhibitor of ERK completely blocked TPA induced miR-101 expression.
Conclusions: Therefore, this is the first time to show that PKCα and ERK pathway play important role to activate miR-
101 expression, reduce PRC2 complex and H3K27me3 level. This epigenetic regulatory pathway may represent a novel 
mechanism of carcinogenesis and deserve further investigation.
Background
MicroRNAs (miRNAs) have been shown to regulate gene
expression either at the post-transcriptional or at the
translational levels [1]. Recent analysis of global miRNA
expression profile in various cancer tissues has revealed
significant alteration of a specific set of miRNA in breast,
lung, pancreas tumors and leukemia [2,3]. The cause and
consequences of miRNA dysregulation in cancer has
been intensively reviewed recently [4]. MicroRNAs have
also been shown to play important role in cell cycle con-
trol [5]. For example, members of the miR-290 cluster
were shown to regulate the G1/S phase transition in
embryonic stem cell [6]. Overexpression of miR-203 was
shown to induce the differentiation of human keratino-
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cytes [7,8]. However, very little is known about how
miRNA itself was regulated under various physiological
conditions.
PKC is a member of serine/threonine kinase whose iso-
forms have been shown to be involved in a number of cel-
lular processes, including cell proliferation, apoptosis,
invasion and migration [9,10]. Various PKC isoforms
have been identified, including the conventional PKCs
(cPKC-α, cPKC-βI, cPKC-βII, and cPKC-γ), novel PKCs
(nPKC-δ, nPKC-ε, and nPKC-η), and atypical PKCs
(aPKCζ) [11]. In vitro and in vivo studies clearly docu-
mented that PKC signaling has the potential to regulate
cell proliferation [12,13]. Previous studies have shown
that TPA activates protein kinase C alpha and induces
growth arrest of human hepatoma HepG2 cells [14].
However, whether there is any miRNA involved in PKCα-
mediated cell growth arrest is still unknown.
MiR-101 was shown to promote apoptosis and suppress
FOS oncogene expression in human hepatoma cells and
to act as tumor suppressor gene in carcinogenesis of
human hepatoma [15,16]. The targets of miR-101 include
EZH2 and EED, two key component of PRC2 complex.
PRC2 is responsible for genome wide methylation of his-
tone 3 lysine 27 [17]. Therefore, down regulation of miR-
101 in HCC may increase PRC2 complex, enhance meth-
ylation of histone H3 lysine 27 at specific genome loci and
epigenetically regulate gene expression at genome wide
level.
I n  t h i s  s t u d y ,  w e  e x a m i n e d  T P A  r e g u l a t e d  m i R N A
expression profile in human hepatoma HepG2 cells and
discovered that miR-101 was induced by TPA in HepG2
cells. We also showed the induction of miR-101 by TPA is
PKCα and ERK dependent. This result opens a new direc-
tion to study molecular mechanism of dysregulation of
miRNA expression in human HCC in the future.
Methods
Plasmid constructs and cell lines
Lentiviral plasmids of Clone ID: TRCN0000001692 encod-
ing a shRNA targeting region of PKCα mRNA were
obtained from The RNAi Consortium (TRC), National
RNAi Core Facility, Academia Sinica, Taiwan. The
3'untranslated regions of EED (1~211) and EZH2 (1~263)
were prepared by PCR using NPC-TW02 cells cDNA and
cloned into MluI/SpeI sites of pMIR-REPORT™ (Ambion,
Austin, TX). MiR-lacZ 5'-TGCTGAAATC GCTGATTT-
GTGTAGTCGTTTTGGCCACTGACTGACG ACTA-
CACATCAGCGATTT-3' cloned into SmaI/NcoI sites of
pLenti-6.4 (Invitrogen, Taiwan). MiR-101-1:5'-TGCCCTG
GCTCAGTTATCACAGTGCTGATGCTGTCTATTCTA
AAGGTACAGTACTGTGATAACTGAAGGATGGCA-3'
and miR-101-2: 5'-ACCACCATTCTTCAG TTATCAC
AGTACTGTACCTTTCAGATATACAGCATCGGTAC C
ATGATAACCGAAAAAGGACAGT-3' were cloned into
SmaI/XmaI sites of pLenti-6.4. HEK 293T, HEK 293 and
HepG2 cells were obtained from American Type Culture
Collection (Rockville, MD). Cells were grown in Dul-
becco's modified Eagle's medium (DMEM; Invitrogen, Tai-
wan) supplemented with 10% (v/v) fetal bovine serum, 2
mM L-glutamine, penicillin (1000 U/ml), and streptomy-
cin (50 μg/ml) with 5% CO2 at 37°C.
Cell transfection and antibodies
Transfection of plasmid DNA into cultured cell was per-
formed using the standard calcium phosphate precipita-
tion method [18]. Cells were plated in 12-well dishes with
5 × 105 cells/well 24 hours before transfection. Anti-β-
actin (AC-15) was purchased from Sigma (St. Louis,
MO). Anti-EED was purchased from Upstate Biotechnol-
ogy. Anti-EZH2 (AC22), and anti-Tri-Methyl-Histone H3
(Lys27) (C36B11) antibodies were purchased from Cell
Signaling Technology (Beverly, MA). Anti-PKCα (C-20),
Anti-PKCε (C-15) were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Anti-PKCδ was purchased
from Transduction Laboratories (Lexington, KY). TPA
(12-O-tetradecanoylphorbol 13-acetate) was purchased
from Sigma (St. Louis, MO). Precursors of respective
miR-101 and negative controls were purchased from
Ambion (Austin, TX).
Immunoblotting analysis
Cells were washed with ice-cold PBS twice and lysed in
500 μl of chilled RIPA buffer (50 mM Tris-HCl pH 7.4,
150 mM NaCl, 1 mM PMSF, 1 mM EDTA, 1% Triton X-
100, 1% Sodium deoxycholate, 0.1% SDS) with protease
inhibitor cocktail from Roche Diagnostics Ltd (Lewes,
U.K). The cell debris was removed by centrifugation for
10 min at 14000 rpm in an Eppendorf microcentrifuge.
The supernatant was added with SDS sample buffer (100
mM Tris, 25% glycerol, 2% SDS, 0.01% bromophenol
blue, pH 6.8) containing 5% β-mercapto-ethanol and
boiled for 10 min. Whole cell lysates were resolved by
SDS-polyacrylamide electrophoresis. After transferred to
nitrocellulose membranes (PerkinElmer Life science), the
membranes were blocked in 5% non-fat milk/TTBS (25
mM Tris-HCl, pH 7.4, 137 mM NaCl, 3 mM KCl, and
0.2% Tween 20) followed by incubation with the indicated
primary antibodies. Membranes are then incubated with
horseradish peroxidase-conjugated secondary antibodies
and levels of proteins of interest were detected by ECL
chemi-luminescence reagents as described (Visual Pro-
tein Biotechnology Corp.).
RNA extraction and quantitative reverse transcription PCR 
(Q-PCR)
Total RNA was prepared using TRIzol reagent (Invitro-
gen) according to the manufacturer's protocol. For quan-
titative measurement of miRNA, stem-loop RT-qPCRChiang et al. Journal of Biomedical Science 2010, 17:35
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assay was performed as described [19]. Briefly, 1 μl of
diluted RT product was used as template for a 10 ml PCR.
The PCR reaction mixture contains 1× SYBR Master Mix
(Applied Biosystem, Foster City, CA, USA), 200 nM miR-
NAs-specific forward primer, and 200 nM universal
reverse primer. The condition for Q-PCR is 95°C for 10
min, followed by 40 cycles of 95°C for 15 s and 63°C for 32
s, and a dissociation stage [20]. For mRNA Q-PCR reac-
tion, the following PCR conditions were used: 95°C for 10
min, followed by 45 cycles of 95°C for 15 s and 60°C for 1
min, and a dissociation stage [20]. An ABI Prism 7500
Fast Real-Time PCR system (Foster City, CA, USA) was
used for Q-PCR reactions. The threshold cycle (Ct) and
relative quantification (RQ) were calculated by using the
ABI 7500 SDS 1.3.1 software. The primers used in Q-PCR
are shown in Table 1.
Data processing
The threshold cycle (Ct) is defined as the cycle number at
which the change of fluorescence intensity crosses the
threshold of 0.2. The raw Ct data were converted to 39-Ct
after normalized by global median normalization before
further analysis. Student's T-test was performed to iden-
tify differentially expressed (DE) miRNAs (p < 0.05) and
those miRNAs with a fold-change less than 2 were then
filtered. For mRNA expression, the average Ct of β-2-
microglobulin (B2M) was subtracted from the raw Ct
value to obtain ΔCt (dCt). Because any Ct value greater
than 40 is considered undetectable, the experimentally
normalized dCt values were converted to 39-Ct and used
to represent the expression level of human mRNA tran-
scripts. The DE genes were identified by one-way
ANOVA and calculate q-value (false discovery rate).
Genes with more than 10% FDR and less than 1.5-fold
changes were filtered out. Partek® Genomics Suite (ver-
sion 6.4, St Louis, MO, USA) was used for all statistical
analyses.
Luciferase reporter assay
Cells were co-transfected microRNA expression vector
pLenti-6.4 containing miR-101-1, miR-101-2, or miR-
LacZ, with pMIR-REPORT constructs of EED-
3'UTR(1~221) and EZH2-3'UTR(1~263), and Rous sar-
coma virus-β-galctosidase vector to monitor transfection
efficiency. Forty-eight hours after transfection, cell
extracts were analyzed for luciferase and β-galactosidase
activities using the Dual-Light Kit (Tropix) according to
the manufacturer's instruction. Luciferase activity was
normalized to β-galactosidase activity and expressed as
fold stimulation relative to vector-transfected cells.
Results shown are averages of three separate experiments
performed in triplicate. Values are expressed as means ±
s.d.
Cell proliferation assay
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tet-
razolium bromide; Sigma] reduction assays were per-
formed as previously described [21]. HepG2 cells were
seeded in 24-well plates overnight in DMEM containing
10% (v/v) FBS. Before colorimetric determination of
MTT reduction, MTT was added to a final concentration
of 0.5 mg/ml, and incubation was continued for another 4
h before adding the cell lysis buffer [20% (w/v) SDS and
50% (v/v) N,N-dimethylformamide, pH 7.4]. The colori-
metric determination of MTT reduction was performed
at the wavelength of 570 nm.
Results
TPA-induced growth arrest in HepG2 is PKCα-dependent
Previous studies have shown that PKCα may play an
important role in TPA-induced growth arrest in HepG2
cells [14]. To re-examine whether the PKCα is required
for TPA-mediated cell arrest in HepG2 cells, we knocked
down the expression of endogenous PKCα in HepG2 cells
using a lentiviral-based PKCα shRNA. We found that
TPA induced cell arrest in HepG2 cells was largely abol-
ished in PKCα knockdown HepG2 cells (Fig. 1A). The
lentiviral-based PKCα shRNA specifically knocked down
only PKCα and has no effect on the expression of two
other PKC isoforms, PKCδ and PKCε, in the HepG2 cells
(Fig. 1B).
Identification of key regulatory miRNA in TPA induced 
growth arrest in HepG2 cells
To identify miRNAs with novel regulatory activity, we
hypothesized that any miRNA plays key regulatory role in
TPA-induced cell growth arrest should also shown
altered expression pattern in human hepatoma tissues.
We first surveyed the expression profile of 270 human
miRNAs in 20 pairs of human hepatoma tissues. Using
Student's T-test and Mann-Whitney rank test, we identi-
fied 11 up-regulated and 23 down-regulated miRNAs
(FDR ≤ 0.01; fold-change ≥ 2) in human hepatoma tissue
(Figure 2A). We then examined the miRNA expression
profile in TPA treated HepG2 cells. Two miRNAs, miR-
101, and miR-29c, were found significantly down regu-
Table 1: Q-PCR primers.
Name Forward primer Reverse primer
hsa-miR-101 CGGCGGTACAGTACTGTGATAA Universal stem-
loop primer*
hsa-miR-29c CGGCGGTAGCACCATTTGAAAT
hsa-miR-122 CGGCGGTGGAGTGTGACAATGG
hsa-miR-16 CGGCGGTAGCAGCACGTAAATA
B2M AGGACTGGTCTTTCTATCTCT TTCATCCAATCC
AAATGCGG
* The universal stem-loop primer: CTGGTGTCGTGGAGTCGGCAATTCChiang et al. Journal of Biomedical Science 2010, 17:35
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lated in human hepatoma tissues and induced over 4-fold
in HepG2 cells upon TPA treatment (Fig 2B; Table 2).
The induction kinetics of both miR-101 and miR-29c in
HepG2 cells after TPA treatment were examined. Inter-
estingly, these two miRNAs showed completely different
induction kinetics after TPA treatment in HepG2 cells.
MiR-101 was rapidly induced by TPA at 3 hrs and
reached maximum level of induction at 12 hrs. On the
other hand, miR-29c only showed slight induction after
12 hrs and reached maximum level of induction at 48 hrs.
The rapid induction of miR-101 by TPA treatment indi-
cates that the induction of miR-101 may be the primary
response of TPA treatment in HepG2 cells (Fig 2C).
TPA-induced miR-101 and its downstream effects are all 
PKCα-dependent in HepG2 cells
To study how TPA induced miR-101 expression in
HepG2 cells, we examined miR-101 expression in both
parental HepG2 and PKCα knockdown HepG2 cells
under TPA treatment. As shown in Fig. 3A, TPA induced
miR-101 expression was largely abolished in the PKCα
knockdown HepG2 cells. This result clearly indicates that
TPA-induced miR-101 expression in HepG2 cells is PKCα
dependent.
EZH2 and EED are key components of PRC2 complex,
a critical epigenetic modulator responsible for genome
wide methylation of histone 3 lysine 27. EZH2 and EED
have been shown as the target gene(s) of miR-101 [17,22].
To examine the effect of miR-101 on these two targets, we
first analyzed and identified the miR-101 recognition
sequence in the 3' UTR regions of EZH2 and EED using
our in-house TargetScan program (Fig. 3B). There are
two predicted miR-101 precursor hairpin structures,
miR-101-1 and miR-101-2, in the human genome. Both
predicted miR-101 precursors generate identical mature
miR-101. MiR-101-1 is an intergenic miRNA gene
located in chromosome 1p31.3. miR-101-2 is located in
chromosome 9p24.1 and is mapped to the intron of a host
gene RCL-1 whose function is still not clear [23]. To
experimentally validate that the predicted target
sequences of miR-101 can be suppressed by both miR-
101-1 and miR-101-2, we cloned these two miR-101 pre-
cursor sequences into the pMIR-REPORT™ and perform
luciferase activity assay. As shown in Fig. 3C, when the
luciferase gene carried 3' UTR region of either EZH2 or
EED's transcript, the luciferase activity was inhibited by
over-expressing miR-101-1 or miR-101-2 but not by the
control miR-LacZ. Similar results were obtained in both
HepG2 and HEK293 cells.
If TPA-induced miR-101 expression is PKCα-depen-
dent, all TPA-induced miR-101 down stream effects such
as reduced level of EZH2 and EED protein and methyla-
tion of histone 3 lysine 27 should also be PKCα-depen-
dent. As shown in Fig. 3D, TPA treatment indeed
reduced protein level of EZH2, EED, SUS12 and histone
H3 with tri-methylated lysine 27 in parental HepG2 cells.
However, in the PKCα knockdown HepG2 cells, TPA has
no effect on protein level of EZH2, EED, SUS12 and his-
tone H3 with tri-methylated lysine 27. Cell cycle inhibitor
p21 was used as a positive control, since it has been
shown before that TPA induced p21 in HepG2 cells is
PKCα dependent.
TPA-induced miR-101 in HepG2 is mediated by ERK 
signaling pathway
To further identify signaling pathway downstream of
PKCα is crucial for TPA induced miR-101 expression, we
examined whether the ERK signaling is involved using
specific ERK signaling pathway inhibitors. We pretreated
HepG2 cells with the specific MAPK inhibitor, U0126 (10
μM), for 30 minutes and then treated cells with TPA for 8
hrs. We found that pretreatment of U0126 completely
blocked TPA induced miR-101 expression in HepG2 cells
(Fig. 4A). As a control, U0126 blocked TPA induced ERK
activation and p21 expression (Fig. 4B).
Figure 1 TPA-induced growth arrest in HepG2 is PKCα-depen-
dent. (A) 1 × 105 of parental HepG2 and PKCα knockdown HepG2 cells 
were seeded in 24 well plates. After culturing in serum-free medium for 
24 hrs, cells were treated with TPA 100 nM in serum-free medium for 
indicated time before MTT analysis. The cell proliferation rate were an-
alyzed using Day6 as 100%. Results shown are averages of three inde-
pendent experiments performed in triplicates. (B) The expression 
profile of different PKC isoforms in parental HepG2 and HepG2 PKCα 
knockdown stable lines were examined by Western blot analysis.Chiang et al. Journal of Biomedical Science 2010, 17:35
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Figure 2 Identification of key regulatory miRNA in TPA induced growth arrest in HepG2 cells. (A) Expression levels of 270 miRNAs in 20 pairs of 
human HCC tissues. The labeled miRNAs were inversely modulated in TPA-treated HepG2 cells and dotted lines indicate the 2-fold change threshold. 
Expression levels of miRNA were presented as 39-Ct. (B) Expression levels of miR-29c and miR-101 in 20 pair of human HCC tissues and their adjacent 
normal tissues. Expression levels of miRNA were presented as 39-Ct. p-values were calculated using T-test. (C) Time-dependent changes in miR-101, 
miR-29c and miR-122 expression levels. HepG2 cells were treated with 100 nM TPA for indicated time periods and the total RNAs were collected for 
stem-loop RT-qPCR. Expression levels of miR-101, miR-29c and miR-122 were normalized to miR-16 and expressed as fold-change using time 0 as 
baseline.Chiang et al. Journal of Biomedical Science 2010, 17:35
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Discussion
PKC is a family of phospholipid-dependent serine/threo-
nine kinase and involves in various cellular processes
such as cell proliferation, apoptosis, invasion and migra-
tion. Previous studies have shown that activation of PKC
alpha is required for TPA-induced ERK signaling to trig-
ger gene expressions of p15(INK4b) and p16(INK4a)
leading to HepG2 growth inhibition [24]. Recent studies
further identified transcriptional factor Snail is up-regu-
lated by PKC alpha and is responsible for inducing
p15(INK4b) expression [25,26]. However, any other novel
regulator such as miRNA involved in TPA induced
growth arrest of HepG2 cells is still unknown. In this
study, we demonstrated that TPA-induced ERK signaling
pathway in HepG2 cells can up-regulate expression of
tumor suppressor gene miR-29c and miR-101.
Several studies have shown that miR-29c is down-regu-
lated in nasopharyngeal carcinomas, chronic lympho-
cytic leukemia (CLL), and lung cancer which were
correlated with up-regulating target genes in extracellular
matrix proteins and DNA methyltransferase (DNMT) 3A
and -3B [27-29]. Whether miR-29c is also involved in reg-
ulating HepG2 cell growth still needs more studies in the
future.
MiR-101 recently has been shown to act as an impor-
tant tumor suppressor gene in various human cancers
including prostate and liver cancer [16,17,22]. Two essen-
tial components of PRC2 complex, EZH2 and EED, have
been shown as target of miR-101 [17]. PRC2 is responsi-
ble for genome wide methylation of histone 3 lysine 27
[17]. Therefore, we hypothesized that down regulation of
miR-101 in HCC may increase PRC2 complex, enhance
methylation of histone H3 lysine 27 at specific genome
locus and epigenetically regulate gene expression at
genome wide level.
Based on this hypothesis, the first question should be
answered is how expression of miR-101 is down regulated
during development of human cancers. MiR-101 can be
expressed from two genomic loci, miR-101-1 on chromo-
some 1p31 and miR-101-2 on chromosome 9p24. Both
loci produce identical mature miR-101. Therefore, it
becomes difficult to differentiate transcriptional regula-
tion of one locus from the other. Only one study convinc-
ingly showed that genomic deletion of miR-101 at both
loci occurs in a significant number of human prostate
cancer and was associated with cancer progression [17].
In our study, we showed unequivocally that activation
of PKCα and ERK by TPA can induce expression of miR-
101 in HepG2 cells. Our results suggest that in human
HepG2 cells the genomic loss may not be responsible for
down regulation of miR-101 expression. This conclusion
was supported by the results of genomic PCR analysis.
No genomic deletion at either miR-101 locus was
detected in HepG2 cells (data not shown).
Our study also provided first experimental evidence to
show that induction of endogenous miR-101 indeed is
accompanied with lower EZH2, EED and SUZ12 level
and histone 3 lysine 27 trimethylation in human hepa-
toma cells. These results indicate that the expressed miR-
101 in HepG2 cells is fully functional and no obvious
abnormality is associated with microRNA processing
machinery in HepG2 cells.
One interesting question raised from our observation is
why TPA also down regulated SUZ12 even though only 3'
UTR of EZH2 and EED's transcript carry miR-101 target
sequence. Similar phenomenon has also been observed
when miR-101 was ectopically overexpressed in human
prostate cancer cells [17]. The authors suspected that
miR-101 reduced the level of EZH2 and lead to destabili-
zation of SUZ12. However, we cannot rule out the possi-
bility that activation of PKCα may also down regulate
SUZ12 expression in a miR-101-independent manner. We
are currently investigating this possibility.
Our study provides us an excellent model to examine
how expression of miR-101 is normally regulated and
leads a new direction of investigation to elucidate possi-
ble defective regulatory pathway of miR-101 expression
in human hepatoma cells.
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